AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6138055
Drug: Loprazolam (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loprazolam (1.0 mg) + Alcohol (0.7 g/kg body weight)
Trial: 31189966
Drug: Sulfonylurea treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfonylurea treatment (any type)
Trial: 27593569
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy sessions
Trial: 27593569
Drug: Child-focused therapy
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child-focused therapy sessions
Trial: 27593569
Drug: Context-focused therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Context-focused therapy sessions
Trial: 22170010
Drug: Candesartan (±
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (± thiazide‐diuretics)
Trial: 14686231
Drug: Oral valganciclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral valganciclovir
Trial: 31862739
Drug: Topical 2%
RxNorm normalized name: menthol topical 2% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 2% ganciclovir
Trial: 17668528
Drug: Retinoid-containing combination
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retinoid-containing combination regimens with oral antibiotics
Trial: 17668528
Drug: Retinoid-containing combination
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retinoid-containing combination regimens with topical benzoyl peroxide and antibiotics
Trial: 11260098
Drug: Intermittent intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent intravenous morphine infusion on demand (PCA group)
Trial: 7849233
Drug: Formulation B
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation B (solution)
Trial: 7849233
Drug: Formulation A
RxNorm normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation A (powder)
Trial: 3071461
Drug: Ketanserin (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (up to 80 mg daily)
Trial: 28562435
Drug: Calcium hydroxylapatite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium hydroxylapatite (CaHA) treatment
Trial: 19102147
Drug: Forearm-suspending band
RxNorm normalized name: Band-Aid Hurt-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forearm-suspending band immobilization and functional exercise therapy
Trial: 16907901
Drug: Benzocaine/tyrothricin sucking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzocaine/tyrothricin sucking lozenges with conscious sedation
Trial: 3304118
Drug: emepronium (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: emepronium (600 mg/d)
Trial: 3304118
Drug: terodiline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terodiline (50 mg/d)
Trial: 28533679
Drug: rosuvastatin 20
RxNorm normalized name: rosuvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 20 mg alone
Trial: 28533679
Drug: rosuvastatin 20
RxNorm normalized name: rosuvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 20 mg plus EGCG 300 mg on Day 4
Trial: 17163254
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no etidronic acid therapy)
Trial: 12665756
Drug: Hyoscine‐N‐butylbromide injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine‐N‐butylbromide injection
Trial: 12665756
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution administered intraluminally
Trial: 12665756
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution administered intramuscularly
Trial: 10719808
Drug: Late addition
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late addition of G-CSF
Trial: 10719808
Drug: Early addition
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early addition of G-CSF
Trial: 30852486
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine Zhiyi decoction
Trial: 22480387
Drug: Olanzapine-fluoxetine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine-fluoxetine combination (6/50-18/50 mg/d)
Trial: 22480387
Drug: Fluoxetine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (50 mg/d)
Trial: 22480387
Drug: Olanzapine (6-18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (6-18 mg/d)
Trial: 9719976
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia (TA)
Trial: 24325105
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses Ulinastatin (20,000 U/kg)
Trial: 24325105
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses Ulinastatin (5,000 U/kg)
Trial: 18405788
Drug: Alogliptin 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin 100 mg
Trial: 18405789
Drug: Alogliptin 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin 200 mg
Trial: 18405788
Drug: Alogliptin 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin 400 mg
Trial: 18405789
Drug: Alogliptin 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin 800 mg
Trial: 9176996
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg (+)S-ibuprofen arginine
Trial: 9176996
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg (−)R-ibuprofen arginine
Trial: 9176996
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg racemic ibuprofen arginine
Trial: 9176996
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg (+)S-ibuprofen arginine and 400 mg (−)R-ibuprofen arginine
Trial: 9176996
Drug: (−)R-ibuprofen arginine
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: (−)R-ibuprofen arginine
Trial: 4037034
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg nadolol
Trial: 6150945
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg nadolol
Trial: 24524601
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg qn or other statin equivalent to 20 mg atorvastatin
Trial: 18694978
Drug: Load group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Load group (priming dose of 0.07 units of regular insulin per kg body weight followed by 0.07 unit x kg(‐1) x h(‐1) i.v.)
Trial: 18694978
Drug: Twice no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice no load group (infusion of regular insulin of 0.14 x kg(‐1) x h(‐1) without a loading dose)
Trial: 18694978
Drug: No load
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No load group (infusion of regular insulin of 0.07 unit . kg body weight(‐1) x h(‐1) without a loading dose)
Trial: 16534238
Drug: OKT3 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OKT3 therapy in addition to tacrolimus
Trial: 12751506
Drug: Local infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infiltration of lidocaine (1% lidocaine, 1 ml)
Trial: 10687338
Drug: MS:DM (morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MS:DM (morphine sulfate and dextromethorphan hydrobromide)
Trial: 9494946
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine and abstinence from smoking
Trial: 9399390
Drug: Cisapride 20
RxNorm normalized name: cisapride 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 20 mg at night
Trial: 8444088
Drug: Cisapride 10
RxNorm normalized name: cisapride 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 10 mg twice daily
Trial: 3023556
Drug: High-dose cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cisplatin (120 mg/m2 day 1) + etoposide (120 mg/m2 days 3, 5, and 7)
Trial: 3023556
Drug: Standard-dose cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose cisplatin (60 mg/m2 day 1) + etoposide (120 mg/m2 days 3, 5, and 7)
Trial: 22210576
Drug: Fenofibrate (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate (200 mg daily)
Trial: 19703381
Drug: Overall ECT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall ECT treatment
Trial: 28271733
Drug: Insulin Glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin Glulisine (IG) once daily (QD)
Trial: 28271733
Drug: Insulin Glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin Glulisine (IG) three times daily (TID)
Trial: 12649711
Drug: Co-amoxiclav 500
RxNorm normalized name: CO
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-amoxiclav 500 mg amoxicillin/125 mg clavulanic acid t.i.d. for 10 days
Trial: 11289194
Drug: Gatifloxacin 400
RxNorm normalized name: gatifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gatifloxacin 400 mg
Trial: 9538976
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro (LP)
Trial: 1287139
Drug: Ofloxacin (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (oral administration)
Trial: 1287139
Drug: Sulbactam-ampicillin (parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulbactam-ampicillin (parenteral administration)
Trial: 31695482
Drug: Inhaled aromatherapy
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled aromatherapy with peppermint essence
Trial: 16367988
Drug: Methylphenidate (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (up to 0.6 mg/kg/day)
Trial: 9725543
Drug: Zolmitriptan 20
RxNorm normalized name: Zolmitriptan
DrugBank: Zolmitriptan (DB00315)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zolmitriptan 20 mg
Trial: 9725543
Drug: Zolmitriptan (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolmitriptan (5 mg, 10 mg, 20 mg)
Trial: 2567714
Drug: Alternate-day FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternate-day FSH therapy
Trial: 20433807
Drug: MF59-adjuvanted subunit
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59-adjuvanted subunit vaccine
Trial: 10462245
Drug: Non-adjuvanted subunit
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adjuvanted subunit vaccine
Trial: 12621386
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam (0.025 mg/kg)
Trial: 12621386
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam (0.15 mg/kg)
Trial: 6616987
Drug: verapamil (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: verapamil (0.1 mg/kg i.v., followed by an infusion of 0.01 mg/kg/min)
Trial: 24500418
Drug: Tipifarnib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tipifarnib (200 mg/m² orally every 12 hours)
Trial: 22180622
Drug: 3-dose regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-dose regimen of intravenous artesunate (given at 0, 24, and 48 hours)
Trial: 1686250
Drug: CCK-4 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCK-4 (25 μg)
Trial: 1686250
Drug: CCK-4 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCK-4 (50 μg)
Trial: 16351364
Drug: Daily experiences
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily experiences of identity denial
Trial: 2183405
Drug: Aspirin (325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (325 mg/day)
Trial: 2244556
Drug: Heparin followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin followed by warfarin
Trial: 2244556
Drug: Aspirin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (80 mg/day) plus heparin and then warfarin
Trial: 31739434
Drug: IV dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV dexamethasone (8 mg per day/40 mg total for 5 days)
Trial: 31739434
Drug: L-lysine aescinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-lysine aescinate (5 mL for group 2 and 10 mL for group 3)
Trial: 31739434
Drug: Baseline therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline therapy with lornoxicam (16 mg per day)
Trial: 28627217
Drug: Plantar electrical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plantar electrical stimulation therapy (IG: n = 17)
Trial: 16397290
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g aspirin, 3 times daily for 6 days
Trial: 3539632
Drug: Intravenous infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusions of prostacyclin
Trial: 3539632
Drug: Placebo (solvent)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (solvent) infusions
Trial: 22434343
Drug: Nicotine stimuli
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine stimuli at concentrations of 99 and 134 ng/mL
Trial: 14678066
Drug: Lozenge, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lozenge, 2 mg or 4 mg
Trial: 3827157
Drug: labetalol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: labetalol (mean dose = 235 +/- 47.5 mg/day)
Trial: 26869339
Drug: Battlefield Acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Battlefield Acupuncture (BFA) protocol, eight-week once weekly ten-needle treatment (n=13)
Trial: 26691209
Drug: Pentoxifylline (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (400 mg three times per day for 28 days)
Trial: 26691209
Drug: Placebo (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (in combination with prednisolone)
Trial: 26691209
Drug: Placebo (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (in combination with pentoxifylline)
Trial: 21398006
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (808 nm, 100 mW, 60 seconds, 7.64 J/cm²)
Trial: 17074107
Drug: rosiglitazone 4
RxNorm normalized name: rosiglitazone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone 4 mg/d plus 5-aminosalicylic acid (5-ASA) 2 g/d
Trial: 12736113
Drug: Carboplatin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (300 mg/m(2), i.v., day 1) and cisplatin (100 mg/m(2), i.v., day 2)
Trial: 12736113
Drug: Cyclophosphamide (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (600 mg/m(2), i.v., day 1) and cisplatin (100 mg/m(2), i.v., day 2)
Trial: 12736113
Drug: Platinum dose-intensified
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum dose-intensified arm
Trial: 3777829
Drug: Netilmicin plus
RxNorm normalized name: netilmicin
DrugBank: Netilmicin (DB00955)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Netilmicin plus metronidazole (administered for one day)
Trial: 3777829
Drug: Doxycycline (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (administered for five days)
Trial: 28976844
Drug: Injection at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection at site X (over the root apex)
Trial: 28976844
Drug: Injection at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection at site Y (over the midpoint)
Trial: 23687948
Drug: Prandial insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prandial insulin aspart with NPH insulin
Trial: 23687948
Drug: Human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human insulin with NPH insulin
Trial: 19824222
Drug: Tesofensine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tesofensine 0.25 mg
Trial: 19824222
Drug: Tesofensine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tesofensine 0.5 mg
Trial: 16648042
Drug: CHOP-like chemotherapy
RxNorm normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHOP-like chemotherapy alone (n=411)
Trial: 16648042
Drug: CHOP-like chemotherapy
RxNorm normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHOP-like chemotherapy plus rituximab (n=413)
Trial: 2741997
Drug: Functional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional treatment
Trial: 10915096
Drug: Women (adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women (adjusted for CD4 T cell count, race or ethnicity, injection drug use, and age)
Trial: 9816176
Drug: Methotrexate/cytarabine infusions,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate/cytarabine infusions, n = 69 (low-risk) and n = 248 (all risk groups)
Trial: 26526160
Drug: PULSE Program
RxNorm normalized name: PUMP,LUTREPULSE PROGRAMMABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PULSE Program (self-administered lifestyle intervention)
Trial: 17261285
Drug: 0.05 mg
RxNorm normalized name: biotin 0.05 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg ethinyl‐E(2) (EE) three times a day for 2 weeks
Trial: 11345387
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone (1 mg/kg) plus four additional intravenous doses over 24 h
Trial: 9338902
Drug: Intravenous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous saline placebo
Trial: 3071617
Drug: Cefotaxime (CTX)
DrugBank: Cefotaxime (DB00493)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefotaxime (CTX) + Fosfomycin (FOM) administration
Trial: 3071617
Drug: Cefotaxime (CTX)
DrugBank: Cefotaxime (DB00493)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefotaxime (CTX) single administration
Trial: 31983281
Drug: 15 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g/day AXOS for 12 weeks
Trial: 28365464
Drug: Mindfulness-based group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based group therapy (MGT)
Trial: 29180593
Drug: Self-help treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-help treatments (including painkillers)
Trial: 29180593
Drug: Steam inhalation
RxNorm normalized name: Leader Hot Steam Inhalation Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steam inhalation
Trial: 27045520
Drug: Motivational interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational interviewing (MI) + group cognitive behavioral therapy (gCBT)
Trial: 27045520
Drug: Befriending +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Befriending + group cognitive behavioral therapy (gCBT)
Trial: 11774112
Drug: High-dose sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose sequential vitamin B6 and folic acid supplementation
Trial: 26803590
Drug: Vitamin B6
RxNorm normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B6 treatment
Trial: 1674294
Drug: Low-protein diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-protein diet (0.6 g/kg body weight daily; n = 226)
Trial: 1674294
Drug: Controlled-protein diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-protein diet (1.0 g/kg daily; n = 230)
Trial: 1674294
Drug: Low-protein diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-protein diet (0.6 g/kg body weight daily; n = 226) in group A
Trial: 1674294
Drug: Low-protein diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-protein diet (0.6 g/kg body weight daily; n = 226) in group B
Trial: 7022214
Drug: Maintenance doses
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance doses of vinblastine
Trial: 21310305
Drug: 8 g
RxNorm normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 g of mixed fibers
Trial: 21310305
Drug: 12 g
RxNorm normalized name: PEG-12 GLYCERYL LAURATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 g of mixed fibers